This has just popped up in my mailbox: Dear all, Hello from...

This has just popped up in my mailbox:

Dear all,

Hello from Leslie Chong.

It has been an exciting end of 2018 for Imugene.  We have completed our Phase 1b trial in gastric cancer patients!
After announcing last month our trial had met its primary end points of safety, tolerability and selecting a dose to commence Phase 2 trials, this week we announced many of our Phase 1b patients have seen a >30% reduction in tumour size for their best overall response.  Most of the patients dosed on our Phase 1b trial have either stabilised their tumour growth or seen their tumours shrink.
We announced we are cautiously encouraged by these results because that's exactly what we are.  The patient numbers are small and all patients received concomitant standard of care chemotherapy.  The results however give us optimism that embarking on a multi-million dollar Phase 2 trial is the right strategic move and we are excited to get this started in early 2019.

The 14 patient study tested three dose levels of HER-Vaxx (10, 30 and 50 micrograms) in combination with current standard of care chemotherapy, cisplatin and fluorouracil or capecitabine.  All dose levels showed an increased antibody response in patients.

No safety issues were reported and HER-Vaxx was found to be well tolerated.

The study Cohort Review Committee recommended a dose of 50 micrograms for the Phase 2 dose based on the safety and immunogenicity data.

Peer review is the best feedback you can get.  We were very pleased to get reported in the prestigious daily biotechnology forum Fierce Biotech this week.  We now know the companies interested in what we are doing will be up to speed on our progress.  This is critical since Big Pharma are ultimately our customer. Click here to read the Fierce Biotech report.

We look forward to reporting further milestones, obtaining  patient data and commencing the Phase 2 trial in early 2019.
Please click here to view the announcement from earlier this week.

Warmest,

Leslie.​